Wugen Inc., is focused on developing ‘off the shelf’ (i.e. allogeneic) cellular therapies to treat a variety of cancers. Wugen’s best-in-class memory NK cell platform differentiates itself from competitors as its cells have more cytotoxic capability and persist longer in the body, potentially making them more powerful agents to kill cancer cells. Wugen licensed its technology from Washington University in St. Louis, MO.

LocationSt. Louis, MO & San Diego, CA
CEODan Kemp
Partner Bali Muralidhar
Websitewww.wugen.com